IO Frontiers World 2019


Andrea Van Elsas

Dr Andrea Van Elsas

CSO, Aduro Biotech Europe
Andrea van Elsas became Chief Scientific Officer of Aduro Biotech Europe in November 2015. He completed his thesis on melanoma antigens and their use in cancer immunotherapy in 1996 (Leiden University Medical Center). A KWF (Dutch Cancer Society) fellowship allowed him to study manipulation of T cell co-stimulation using antibodies blocking CTLA-4 for the treatment of cancer at the University of California in Berkeley, CA. He is a co-inventor on the original patents that formed the basis for the development of ipilimumab. After his academic career, Andrea joined Organon where he was involved in the foundation of the Organon Research Center in Cambridge, MA. Between 2007 – 2009, he served in Cambridge as Head of Oncology Biologics Discovery for Organon and POC team leader for Schering-Plough’s Immune Oncology portfolio. He managed various discovery alliances with biotech and academia in the field of Oncology and he is a co-founder of BioNovion.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy